Teladoc Health (NYSE:TDOC - Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $639.44 million for the quarter. Investors interested in participating in the company's conference call can do so using this link.
Teladoc Health Trading Up 6.3 %
TDOC traded up $0.85 during trading on Friday, hitting $14.36. The company's stock had a trading volume of 20,718,368 shares, compared to its average volume of 6,465,854. Teladoc Health has a twelve month low of $6.76 and a twelve month high of $21.74. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66. The stock's fifty day moving average price is $10.28 and its 200-day moving average price is $9.28. The firm has a market capitalization of $2.47 billion, a P/E ratio of -2.49 and a beta of 1.05.
Insiders Place Their Bets
In other Teladoc Health news, insider Carlos Nueno sold 2,389 shares of the business's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $11.93, for a total value of $28,500.77. Following the transaction, the insider now owns 2,890 shares of the company's stock, valued at approximately $34,477.70. The trade was a 45.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.95% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on TDOC shares. Piper Sandler reissued an "overweight" rating and issued a $13.00 price target (up from $11.00) on shares of Teladoc Health in a research note on Wednesday, December 4th. Oppenheimer decreased their price objective on Teladoc Health from $14.00 to $12.00 and set an "outperform" rating for the company in a report on Friday, January 24th. TD Cowen decreased their price objective on Teladoc Health from $9.00 to $8.00 and set a "hold" rating for the company in a report on Thursday, October 31st. Royal Bank of Canada boosted their price objective on Teladoc Health from $11.00 to $12.00 and gave the company an "outperform" rating in a report on Friday, January 24th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on Teladoc Health from $10.00 to $12.00 and gave the company a "hold" rating in a report on Friday, November 1st. Fourteen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $12.08.
Get Our Latest Research Report on Teladoc Health
About Teladoc Health
(
Get Free Report)
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Read More
Before you consider Teladoc Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.
While Teladoc Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
